Can Stem Cell Therapy be an Effective Therapeutic Option for Complex and Neurological Conditions?




This article explores the feasibility and potential benefits of stem cell therapy as a promising therapeutic intervention for individuals facing severe behavioral and cognitive impairments, targeting underlying neurological mechanisms to offer potential symptom improvement and function restoration, thereby enhancing the quality of life for patients and potentially alleviating stress and burnout among caregivers. The aims of the study include investigating the efficacy of stem cell therapy in addressing these impairments and evaluating its potential to alleviate caregiver burden. Through a comprehensive review of existing literature, clinical trials, and studies, this research synthesizes the mechanisms of stem cell therapy, potential applications, clinical trial outcomes, caregiver experiences, and economic implications. The methods employed involve analyzing diverse data sources to provide a holistic understanding of the possibilities and challenges associated with stem cell therapy. Key outcomes of the study include highlighting promising results from clinical trials targeting conditions such as autism spectrum disorder, Parkinson's disease, and Crohn's disease, which underscore the transformative potential of stem cell therapy in patient care. Additionally, economic implications suggest potential reductions in healthcare costs and alleviation of financial strain on individuals, families, and healthcare providers. Stem cell therapy represents a paradigm shift in healthcare, promising to redefine treatment approaches and alleviate broader societal burdens associated with complex neurological conditions. The relevance of the study lies in emphasizing the need for continued research, ethical considerations, and multidisciplinary collaboration to ensure the safe and effective integration of stem cell therapy into clinical practice, ultimately offering new hope and improved care for patients, caregivers, and healthcare systems worldwide.


Stem Cell Therapy, Neurological Conditions, Healthcare Cost


Download data is not yet available.


M. J. Maenner et al., “Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2020,” MMWR. Surveillance Summaries, vol. 72, no. 2, 2023, doi: 10.15585/MMWR.SS7202A1.

D. K. Simon, C. M. Tanner, and P. Brundin, “Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology,” Clin Geriatr Med, vol. 36, no. 1, pp. 1–12, Feb. 2020, doi: 10.1016/j.cger.2019.08.002.

N. Sharifzadeh et al., “Intrathecal autologous bone marrow stem cell therapy in children with autism: A randomized controlled trial,” Asia-Pacific Psychiatry, vol. 13, no. 2, p. e12445, Jun. 2021, doi: 10.1111/APPY.12445.

A. K. Sharma et al., “Cell transplantation as a novel therapeutic strategy for autism spectrum disorders: a clinical study,” Am J Stem Cells, vol. 9, no. 5, p. 89, 2020.

D. Siniscalco, S. Kannan, N. Semprún-Hernández, A. A. Eshraghi, A. L. Brigida, and N. Antonucci, “Stem cell therapy in autism: recent insights,” Stem Cells Cloning, vol. 11, pp. 55–67, Oct. 2018, doi: 10.2147/SCCAA.S155410.

M. Tegtmeyer and R. Nehme, “Leveraging the Genetic Diversity of Human Stem Cells in Therapeutic Approaches,” J Mol Biol, vol. 434, no. 3, p. 167221, Feb. 2022, doi: 10.1016/J.JMB.2021.167221.

G. Teskey et al., “Intestinal permeability correlates with behavioural severity in very young children with ASD: A preliminary study,” J Neuroimmunol, vol. 357, p. 577607, Aug. 2021, doi: 10.1016/J.JNEUROIM.2021.577607.

N. S. L. Yeo-Teh and B. L. Tang, “Moral obligations in conducting stem cell-based therapy trials for autism spectrum disorder,” J Med Ethics, vol. 48, no. 5, pp. 343–348, May 2022, doi: 10.1136/MEDETHICS-2020-107106.

M. Yıldız, Y. Demir, A. Kırcalı, and A. Incedere, “Caregiver Burden in Schizophrenia and Autism Spectrum Disorders: A Comparative Study,” Psychiatry Investig, vol. 18, no. 12, pp. 1180–1187, Dec. 2021, doi: 10.30773/PI.2021.0165.

S. H. Zuvekas, S. D. Grosse, T. A. Lavelle, M. J. Maenner, P. Dietz, and X. Ji, “Healthcare Costs of Pediatric Autism Spectrum Disorder in the United States, 2003–2015,” J Autism Dev Disord, vol. 51, no. 8, pp. 2950–2958, Aug. 2021, doi: 10.1007/S10803-020-04704-Z.

S. A. Abdullah, S. A. razak, M. S. B. Yusoff, A. Othman, N. A. Yahaya, and N. Mohamad, “Burnout and Stressor-Related Factors among Caretaker of Children with Chronic Neurological Illness,” Malaysian Journal of Paediatrics and Child Health, vol. 27, no. 2, pp. 7–18, Aug. 2021, doi: 10.51407/mjpch.v27i2.140.

B. K. Matin et al., “Contributing factors to healthcare costs in individuals with autism spectrum disorder: a systematic review,” BMC Health Serv Res, vol. 22, no. 1, pp. 1–20, Dec. 2022, doi: 10.1186/S12913-022-07932-4

J. Qu et al., “Efficacy and Safety of Stem Cell Therapy in Children With Autism Spectrum Disorders: A Systematic Review and Meta-Analysis,” Front Pediatr, vol. 10, p. 897398, May 2022, doi: 10.3389/FPED.2022.897398.

Y. Wu et al., “Can pluripotent/multipotent stem cells reverse Parkinson’s disease progression?,” Front Neurosci, vol. 18, p. 1210447, Jan. 2024, doi: 10.3389/FNINS.2024.1210447.

J. Gordon, G. Lockard, M. Monsour, A. Alayli, H. Choudhary, and C. V. Borlongan, “Sequestration of Inflammation in Parkinson’s Disease via Stem Cell Therapy,” International Journal of Molecular Sciences 2022, Vol. 23, Page 10138, vol. 23, no. 17, p. 10138, Sep. 2022, doi: 10.3390/IJMS231710138.

L. K. Mitchell and P. S. W. Davies, “Pre- and probiotics in the management of children with autism and gut issues: a review of the current evidence,” European Journal of Clinical Nutrition 2021 76:7, vol. 76, no. 7, pp. 913–921, Oct. 2021, doi: 10.1038/s41430-021-01027-9.

T. C. Mohammadi, K. Jazi, A. Bolouriyan, and A. Soleymanitabar, “Stem cells in treatment of crohn’s disease: Recent advances and future directions,” Transpl Immunol, vol. 80, p. 101903, Oct. 2023, doi: 10.1016/J.TRIM.2023.101903.

K. Bahrehbar, M. R. Valojerdi, F. Esfandiari, R. Fathi, S. N. Hassani, and H. Baharvand, “Human embryonic stem cell-derived mesenchymal stem cells improved premature ovarian failure,” World J Stem Cells, vol. 12, no. 8, pp. 857–878, Aug. 2020, doi: 10.4252/WJSC.V12.I8.857.

J. Penney, W. T. Ralvenius, and L. H. Tsai, “Modeling Alzheimer’s disease with iPSC-derived brain cells,” Molecular Psychiatry 2019 25:1, vol. 25, no. 1, pp. 148–167, Aug. 2019, doi: 10.1038/s41380-019-0468-3.

G. Shroff, “A review on stem cell therapy for multiple sclerosis: special focus on human embryonic stem cells,” Stem Cells Cloning, vol. 11, pp. 1–11, Feb. 2018, doi: 10.2147/SCCAA.S135415.

E. Courchesne, V. H. Gazestani, and N. E. Lewis, “Prenatal Origins of ASD: The When, What, and How of ASD Development,” Trends Neurosci, vol. 43, no. 5, pp. 326–342, May 2020, doi: 10.1016/j.tins.2020.03.005.

S. A. Keim et al., “Randomized Controlled Trial of Omega-3 and -6 Fatty Acid Supplementation to Reduce Inflammatory Markers in Children with Autism Spectrum Disorder,” J Autism Dev Disord, vol. 52, no. 12, pp. 5342–5355, Dec. 2022, doi: 10.1007/S10803-021-05396-9.

K. Shigematsu, N. Komori, K. Tahara, and H. Yamagishi, “Repeated infusion of autologous adipose tissue-derived stem cells for Parkinson’s disease,” Acta Neurol Scand, vol. 145, no. 1, pp. 119–122, Jan. 2022, doi: 10.1111/ANE.13547.

E. Aguglia and L. Fusar-Poli, “Still a Long Way to Go. Editorial for the Special Issue ‘Understanding Autism Spectrum Disorder,’” Brain Sciences 2021, Vol. 11, Page 1062, vol. 11, no. 8, p. 1062, Aug. 2021, doi: 10.3390/BRAINSCI11081062.

CDC, “Data & Statistics on Autism Spectrum Disorder | CDC.” Accessed: Apr. 26, 2024. [Online]. Available:

R. Choueiri, W. T. Garrison, and V. Tokatli, “Early Identification of Autism Spectrum Disorder (ASD): Strategies for Use in Local Communities,” Indian J Pediatr, vol. 90, no. 4, pp. 377–386, Apr. 2023, doi: 10.1007/S12098-022-04172-6.

N. Vijiaratnam, T. Simuni, O. Bandmann, H. R. Morris, and T. Foltynie, “Progress towards therapies for disease modification in Parkinson’s disease,” Lancet Neurol, vol. 20, no. 7, pp. 559–572, Jul. 2021, doi: 10.1016/S1474-4422(21)00061-2.

Y. Yang, Y. Peng, Y. Li, T. Shi, Y. Luan, and C. Yin, “Role of stem cell derivatives in inflammatory diseases,” Front Immunol, vol. 14, p. 1153901, Mar. 2023, doi: 10.3389/FIMMU.2023.1153901.

Y. Xu and Q. Wu, “Prevalence trend and disparities in rheumatoid arthritis among us adults, 2005–2018,” J Clin Med, vol. 10, no. 15, p. 3289, Aug. 2021, doi: 10.3390/JCM10153289

K. Cushing and P. D. R. Higgins, “Management of Crohn Disease: A Review,” JAMA, vol. 325, no. 1, pp. 69–80, Jan. 2021, doi: 10.1001/JAMA.2020.18936.

M. E. Burczynski et al., “Molecular classification of Crohn’s disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cells,” Journal of Molecular Diagnostics, vol. 8, no. 1, pp. 51–61, Feb. 2006, doi: 10.2353/jmoldx.2006.050079.




How to Cite

S. Lo and R. Gantioque, “Can Stem Cell Therapy be an Effective Therapeutic Option for Complex and Neurological Conditions?”, Adv. J. Grad. Res., vol. 15, no. 1, pp. 12–21, May 2024.